{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:22:04Z","timestamp":1788009724519,"version":"build-2784847793"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.japh.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:44:22Z","timestamp":1707975862000},"page":"102040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Acyclovir dosing in herpes encephalitis: A scoping review"],"prefix":"10.1016","volume":"64","author":[{"given":"Asma","family":"Aboelezz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-2622","authenticated-orcid":false,"given":"Sherif Hanafy","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0147-9563(98)90009-7","article-title":"Herpes simplex encephalitis: a review","volume":"27","author":"Levitz","year":"1998","journal-title":"Heart Lung"},{"issue":"7","key":"10.1016\/j.japh.2024.02.013_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/521262","article-title":"Herpes simplex encephalitis in Sweden, 1990-2001: incidence, morbidity, and mortality","volume":"45","author":"Hjalmarsson","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1086\/589747","article-title":"The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"47","author":"Tunkel","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM198601163140303","article-title":"Vidarabine versus acyclovir therapy in herpes simplex encephalitis","volume":"314","author":"Whitley","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s13311-016-0433-7","article-title":"Herpes simplex virus-1 encephalitis in adults: Pathophysiology, diagnosis, and management","volume":"13","author":"Bradshaw","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"11","key":"10.1016\/j.japh.2024.02.013_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.paed.2011.07.007","article-title":"Management and outcome in viral meningo-encephalitis","volume":"21","author":"Hartley","year":"2011","journal-title":"Paediatr Child Health"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/jm00286a024","article-title":"Novel substrate of adenosine deaminase","volume":"14","author":"Schaeffer","year":"1971","journal-title":"J\u00a0Med Chem"},{"issue":"5654","key":"10.1016\/j.japh.2024.02.013_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/272583a0","article-title":"9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group","volume":"272","author":"Schaeffer","year":"1978","journal-title":"Nature"},{"issue":"1A","key":"10.1016\/j.japh.2024.02.013_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9343(82)90104-8","article-title":"Acyclovir in severe herpes virus infections","volume":"73","author":"van der Meer","year":"1982","journal-title":"Am J Med"},{"issue":"7633","key":"10.1016\/j.japh.2024.02.013_bib10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/bmj.39408.393137.BE","article-title":"Death delusion","volume":"335","author":"Hellden","year":"2007","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.japh.2024.02.013_bib11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ndt\/gfg119","article-title":"High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study","volume":"18","author":"Hellden","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jcv.2014.09.001","article-title":"Aciclovir-induced neurotoxicity: Utility of CSF and serum CMMG levels in diagnosis","volume":"61","author":"Berry","year":"2014","journal-title":"J\u00a0Clin Virol"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.japh.2024.02.013_bib15","series-title":"StatPearls","article-title":"Acyclovir","author":"Taylor","year":"2024"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib16","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/AAC.02010-15","article-title":"Prospective, controlled study of acyclovir pharmacokinetics in obese patients","volume":"60","author":"Turner","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.japh.2024.02.013_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2024.02.013_bib18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/01.ccm.0000907312.68436.14","article-title":"Impact of obesity on clinical outcomes in patients receiving acyclovir for hsv encephalitis","volume":"51","author":"Carter","year":"2023","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.japh.2024.02.013_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106871","article-title":"Comparison of dosing strategies in obese patients prescribed intravenous acyclovir and evaluation of rate of acute kidney injury","volume":"62","author":"Zelnicek","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.japh.2024.02.013_bib20","series-title":"Acyclovir pharmacokinetics in morbid obesity, abstract 765. In 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington DC, USA","author":"Davis","year":"1991"},{"key":"10.1016\/j.japh.2024.02.013_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113852","article-title":"Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice","volume":"156","author":"Kacirova","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.japh.2024.02.013_bib22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/01.ccm.0000509973.51084.3d","article-title":"Evaluation of Iv acyclovir dosing and nephrotoxicity in critically ill obese and lean patients","volume":"44","author":"Li","year":"2016","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.japh.2024.02.013_bib23","first-page":"E208","article-title":"An evaluation of acyclovir dosing in obesity","volume":"36","author":"Twilla","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.japh.2024.02.013_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijid.2018.07.002","article-title":"Acute kidney injury (AKI) associated with intravenous aciclovir in adults: incidence and risk factors in clinical practice","volume":"74","author":"Ryan","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz121","article-title":"Impact of obesity on acyclovir-induced nephrotoxicity","volume":"6","author":"Barber","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2024.02.013_bib26","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/ofid\/ofaa439.240","article-title":"Assessing the clinical impact of intravenous acyclovir dosing in obese patients: should we be using ideal, adjusted, or total body weight?","volume":"7","author":"Mulvey","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.japh.2024.02.013_bib27","first-page":"3625","article-title":"Herpetic encephalitis: which treatment for which body weight?","volume":"269","author":"Mulatero","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"14","key":"10.1016\/j.japh.2024.02.013_bib28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2146\/ajhp080307","article-title":"Acyclovir-induced renal failure in an obese patient","volume":"66","author":"Hernandez","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"10.1016\/j.japh.2024.02.013_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3109\/00365540903510716","article-title":"Varicella-zoster virus meningoencephalitis in an immunocompetent patient without a rash","volume":"42","author":"Klein","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.japh.2024.02.013_bib30","article-title":"Herpes zoster encephalopathy or acyclovir neurotoxicity: a management dilemma","volume":"2014","author":"Sacchetti","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/1346-8138.13196","article-title":"Neurotoxicity induced by the recommended acyclovir dosing in a dialysis patient with herpes zoster: a case letter","volume":"43","author":"Kageyama","year":"2016","journal-title":"J\u00a0Dermatol"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijantimicag.2016.01.006","article-title":"Pharmacokinetics of acyclovir in a morbidly obese patient with renal impairment","volume":"47","author":"Smith","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"Supplement 2","key":"10.1016\/j.japh.2024.02.013_bib33","first-page":"43","article-title":"Acute renal failure in a obese patient on acyclovir treatment","volume":"10","author":"Ferrari","year":"2016","journal-title":"Ital J Med"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3851\/IMP3313","article-title":"Acute renal failure related to high doses of acyclovir (15 mg\/kg\/8 h) during treatment of varicella zoster virus encephalitis","volume":"24","author":"Martinot","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.japh.2024.02.013_bib35","article-title":"Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: how to dose in obese patients?","volume":"7-8","author":"Sallevelt","year":"2020","journal-title":"Clin Infect Pract"},{"key":"10.1016\/j.japh.2024.02.013_bib36","article-title":"Two cases of a pharmacokinetic interaction between (val)acyclovir and mycophenolate mofetil","volume":"17","author":"Berger","year":"2023","journal-title":"Clin Infect Pract"},{"issue":"8405","key":"10.1016\/j.japh.2024.02.013_bib37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0140-6736(84)92623-0","article-title":"Acyclovir versus vidarabine in herpes-simplex encephalitis - randomized Multicenter study in Consecutive Swedish patients","volume":"2","author":"Skoldenberg","year":"1984","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/0897190016642689","article-title":"Dosing practices of intravenous acyclovir for herpes encephalitis in obesity: results of a pharmacist survey","volume":"30","author":"Wong","year":"2017","journal-title":"J\u00a0Pharm Pract"},{"issue":"11","key":"10.1016\/j.japh.2024.02.013_bib40","first-page":"650","article-title":"Gentamicin therapy","volume":"8","author":"Devine","year":"1974","journal-title":"Drug Intell Clin Pharm"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.1986.03370030107039","article-title":"Acyclovir therapy for herpes-zoster - advantages and adverse-effects","volume":"255","author":"Balfour","year":"1986","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.japh.2024.02.013_bib42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/151.2.362","article-title":"Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster","volume":"151","author":"Bean","year":"1985","journal-title":"J\u00a0Infect Dis"},{"issue":"21","key":"10.1016\/j.japh.2024.02.013_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26216566","article-title":"Critical review of synthesis, toxicology and detection of acyclovir","volume":"26","author":"Wei","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.japh.2024.02.013_bib44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bcp.13216","article-title":"The drugs that mostly frequently induce acute kidney injury: a case\u00a0\u2212 noncase study of a pharmacovigilance database","volume":"83","author":"Pierson-Marchandise","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib45","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jcpt.13464","article-title":"Neurotoxicity associated with acyclovir and valacyclovir: a systematic review of cases","volume":"46","author":"Brandariz-Nunez","year":"2021","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.japh.2024.02.013_bib46","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00431-021-04093-0","article-title":"Factors associated with acyclovir nephrotoxicity in children: data from 472 pediatric patients from the last 10 years","volume":"180","author":"Yalcinkaya","year":"2021","journal-title":"Eur J Pediatr"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.36290\/far.2022.021","article-title":"The importance of therapeutic drug monitoring in acyclovir dosage optimization","volume":"36","author":"Kac\u00ed\u0159ov\u00e1","year":"2023","journal-title":"Klin Farmakol Farm"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib49","first-page":"233","article-title":"Hemodialysis removal of acyclovir","volume":"37","author":"Leikin","year":"1995","journal-title":"Vet Hum Toxicol"},{"issue":"1","key":"10.1016\/j.japh.2024.02.013_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000441-199301000-00007","article-title":"Acyclovir neurotoxicity and nephrotoxicity-the role for hemodialysis","volume":"305","author":"Krieble","year":"1993","journal-title":"Am J Med Sci"},{"issue":"12","key":"10.1016\/j.japh.2024.02.013_bib51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00007611-199412000-00006","article-title":"Acyclovir neurotoxicity: clinical experience and review of the literature","volume":"87","author":"Adair","year":"1994","journal-title":"South Med J"},{"key":"10.1016\/j.japh.2024.02.013_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-20","article-title":"Population pharmacokinetics of intravenous and oral Acyclovir and oral Valacyclovir in pediatric population to optimize dosing regimens","volume":"64","author":"Abdalla","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics9030036","article-title":"Augmented renal clearance in critical illness: an important consideration in drug dosing","volume":"9","author":"Mahmoud","year":"2017","journal-title":"Pharmaceutics"},{"issue":"1A","key":"10.1016\/j.japh.2024.02.013_bib54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0002-9343(82)90088-2","article-title":"Overview of acyclovir pharmacokinetic disposition in adults and children","volume":"73","author":"Blum","year":"1982","journal-title":"Am J Med"},{"issue":"Suppl B","key":"10.1016\/j.japh.2024.02.013_bib55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/12.suppl_B.29","article-title":"Pharmacokinetics of acyclovir after intravenous and oral administration","volume":"12","author":"de Miranda","year":"1983","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7-8","key":"10.1016\/j.japh.2024.02.013_bib56","first-page":"518","article-title":"Evaluation of oral acyclovir therapy","volume":"19","author":"Fletcher","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"issue":"6","key":"10.1016\/j.japh.2024.02.013_bib57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cpt1979266718","article-title":"Acyclovir kinetics after intravenous infusion","volume":"26","author":"de Miranda","year":"1979","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib58","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.xphs.2021.01.003","article-title":"Novel Insights to enhance therapeutics with acyclovir in the management of herpes simplex encephalitis","volume":"110","author":"Gurgel Assis","year":"2021","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.japh.2024.02.013_bib59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.18773\/austprescr.2017.053","article-title":"Drug dosing in obese adults","volume":"40","author":"Barras","year":"2017","journal-title":"Aust Prescr"},{"key":"10.1016\/j.japh.2024.02.013_bib60","article-title":"Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: how to dose in obese patients?","volume":"7-8","author":"Sallevelt","year":"2020","journal-title":"Clin Infect Pract"},{"issue":"1A","key":"10.1016\/j.japh.2024.02.013_bib61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0002-9343(82)90084-5","article-title":"Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals","volume":"73","author":"Whitley","year":"1982","journal-title":"Am J Med"},{"issue":"333","key":"10.1016\/j.japh.2024.02.013_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/01621459.1971.10482216","article-title":"Usefulness of the two-Compartment open model in pharmacokinetics","volume":"66","author":"Metzler","year":"1971","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.japh.2024.02.013_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-20","article-title":"Population Pharmacokinetics of intravenous and oral Acyclovir and oral Valacyclovir in pediatric population to optimize dosing regimens","volume":"64","author":"Abdalla","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.21.3.393","article-title":"Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans","volume":"21","author":"Laskin","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.japh.2024.02.013_bib65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/7.4.399","article-title":"Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection","volume":"7","author":"Brigden","year":"1981","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1A","key":"10.1016\/j.japh.2024.02.013_bib66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0002-9343(82)90090-0","article-title":"Effect of renal failure on the pharmacokinetics of acyclovir","volume":"73","author":"Laskin","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.japh.2024.02.013_bib67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijid.2018.07.002","article-title":"Acute kidney injury (AKI) associated with intravenous aciclovir in adults: incidence and risk factors in clinical practice","volume":"74","author":"Ryan","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.japh.2024.02.013_bib68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1479-5876-8-139","article-title":"The effect of acyclovir on the tubular secretion of creatinine in\u00a0vitro","volume":"8","author":"Gunness","year":"2010","journal-title":"J\u00a0Transl Med"},{"issue":"6","key":"10.1016\/j.japh.2024.02.013_bib69","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0002-9343(88)90313-0","article-title":"Acyclovir-induced renal failure. Clinical course and histology","volume":"84","author":"Sawyer","year":"1988","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.japh.2024.02.013_bib70","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/151.2.362","article-title":"Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster","volume":"151","author":"Bean","year":"1985","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.japh.2024.02.013_bib71","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s13311-016-0433-7","article-title":"Herpes Simplex Virus-1 encephalitis in adults: Pathophysiology, diagnosis, and management","volume":"13","author":"Bradshaw","year":"2016","journal-title":"Neurotherapeutics"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:06:48Z","timestamp":1736302008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1544319124000438"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.02.013","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acyclovir dosing in herpes encephalitis: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102040"}}